659 related articles for article (PubMed ID: 19232032)
61. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
Pratley R; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Garber A; Thomsen AB; Hartvig H; Davies M;
Int J Clin Pract; 2011 Apr; 65(4):397-407. PubMed ID: 21355967
[TBL] [Abstract][Full Text] [Related]
62. Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin.
Engel SS; Seck TL; Golm GT; Meehan AG; Kaufman KD; Goldstein BJ
Endocr Pract; 2013; 19(5):751-7. PubMed ID: 23757615
[TBL] [Abstract][Full Text] [Related]
63. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.
Bailey CJ; Bagdonas A; Rubes J; McMorn SO; Donaldson J; Biswas N; Stewart MW
Clin Ther; 2005 Oct; 27(10):1548-61. PubMed ID: 16330291
[TBL] [Abstract][Full Text] [Related]
64. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
Bosi E; Dotta F; Jia Y; Goodman M
Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
[TBL] [Abstract][Full Text] [Related]
65. [Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. A prospective observational study in austrian primary care].
Ludvik B; Daniela L
Wien Klin Wochenschr; 2011 Apr; 123(7-8):235-40. PubMed ID: 21451952
[TBL] [Abstract][Full Text] [Related]
66. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
[TBL] [Abstract][Full Text] [Related]
67. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.
Yoon KH; Shockey GR; Teng R; Golm GT; Thakkar PR; Meehan AG; Williams-Herman DE; Kaufman KD; Amatruda JM; Steinberg H
Int J Clin Pract; 2011 Feb; 65(2):154-64. PubMed ID: 21235696
[TBL] [Abstract][Full Text] [Related]
68. A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.
Wang W; Ning G; Ma J; Liu X; Zheng S; Wu F; Xu L; O'Neill EA; Fujita KP; Engel SS; Kaufman KD; Shankar RR
Curr Med Res Opin; 2017 Apr; 33(4):693-699. PubMed ID: 28035868
[TBL] [Abstract][Full Text] [Related]
69. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
70. Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin.
Jalaludin MY; Deeb A; Zeitler P; Garcia R; Newfield RS; Samoilova Y; Rosario CA; Shehadeh N; Saha CK; Zhang Y; Zilli M; Scherer LW; Lam RLH; Golm GT; Engel SS; Kaufman KD; Shankar RR
Pediatr Diabetes; 2022 Mar; 23(2):183-193. PubMed ID: 34779103
[TBL] [Abstract][Full Text] [Related]
71. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Schernthaner G; Gross JL; Rosenstock J; Guarisco M; Fu M; Yee J; Kawaguchi M; Canovatchel W; Meininger G
Diabetes Care; 2013 Sep; 36(9):2508-15. PubMed ID: 23564919
[TBL] [Abstract][Full Text] [Related]
72. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.
Dhillon S
Drugs; 2010 Mar; 70(4):489-512. PubMed ID: 20205490
[TBL] [Abstract][Full Text] [Related]
73. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.
Scott R; Wu M; Sanchez M; Stein P
Int J Clin Pract; 2007 Jan; 61(1):171-80. PubMed ID: 17156104
[TBL] [Abstract][Full Text] [Related]
74. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
Buse JB; Rubin CJ; Frederich R; Viraswami-Appanna K; Lin KC; Montoro R; Shockey G; Davidson JA
Clin Ther; 2005 Aug; 27(8):1181-95. PubMed ID: 16199244
[TBL] [Abstract][Full Text] [Related]
75. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Choy M; Lam S
Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
[TBL] [Abstract][Full Text] [Related]
76. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Forst T; Guthrie R; Goldenberg R; Yee J; Vijapurkar U; Meininger G; Stein P
Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
[TBL] [Abstract][Full Text] [Related]
77. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
Hamann A; Garcia-Puig J; Paul G; Donaldson J; Stewart M
Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):6-13. PubMed ID: 18095238
[TBL] [Abstract][Full Text] [Related]
78. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
79. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
Kim HS; Shin JA; Lee SH; Kim ES; Cho JH; Son HY; Yoon KH
Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
[TBL] [Abstract][Full Text] [Related]
80. A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Piccinni MN; D'Angelo A; Fogari E; Maffioli P
Diabetes Technol Ther; 2013 Mar; 15(3):214-22. PubMed ID: 23427864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
